富士莱 reported revenue of ¥0.19B for the period ended 2026-06-30, -17.2% year on year. Net income was ¥-0.01B, a -7.9% net margin on a 14.0% gross margin. The largest revenue line is 医药 at 98% of the total. Free cash flow for the period was ¥0.00B.
| Item | Amount | Y/Y |
|---|---|---|
| Revenue | ¥0.19B | -17.2% |
| Gross profit | ¥0.03B | — |
| Operating income | ¥-0.02B | — |
| Net income | ¥-0.01B | -133.9% |
| Gross margin | 14.0% | Net margin -7.9% |
| Revenue Q/Q | -0.3% | — |
| Segment | Revenue | Share |
|---|---|---|
| 医药 | ¥0.18B | 98.4% |
| 其他(补充) | ¥0.00B | 1.6% |
| Item | Amount | % of revenue |
|---|---|---|
| Cost of revenue | ¥0.16B | 86.0% |
| R&D | ¥0.02B | 8.6% |
| SG&A | ¥0.02B | 13.1% |
| Tax & other | ¥-0.00B | -1.2% |
| Item | Amount |
|---|---|
| Total assets | ¥2.04B |
| Total liabilities | ¥0.21B |
| Shareholders' equity | ¥1.83B |
| Equity / assets | 89.8% |
| Operating cash flow | ¥0.03B |
| Capital expenditure | ¥0.02B |
| Free cash flow | ¥0.00B |
| Cash conversion (OCF / net income) | 183% |
The Sankey chart shows how revenue splits into cost of revenue, R&D and SG&A, and what remains as profit — clean visuals for research decks and social posts.
艾布鲁 ・ 格力博 ・ 恒工精密 ・ 海看股份 ・ 泰恩康 ・ 华新科技 ・ 宇邦新材 ・ 华厦眼科 ・ 铭利达 ・ 汉仪股份 ・ 英华特 ・ 瑞晨环保
Source: Eastmoney · This page shows public filing data only, not investment advice. · Browse all companies